Journal article
Definitive IMRT for Stage III Thymic Carcinoma: A Brief Report and Literature Review
Frontiers in oncology, Vol.6, p.219
10/24/2016
DOI: 10.3389/fonc.2016.00219
PMCID: PMC5075761
PMID: 27822456
Abstract
Introduction: Thymic carcinoma is a rare malignancy often presenting at an advanced stage. Radiation therapy and chemotherapy are often the only treatment options available to physicians.
Methods: A 70-year-old man presented with an unresectable stage Ill thymic tumor and was treated with 45 Gy in 25 fractions followed by a boost of 21.6 Gy in 12 fractions. He was also treated with bortezomib for multiple myeloma unrelated to his primary malignancy.
Results: The patient made a full recovery following the radiation regimen and remained disease free 4 years after the treatment.
Conclusion: Exclusive treatment with intensity modulated radiation therapy provides a viable treatment option for patients presenting with advanced stage thymic carcinoma.
Details
- Title: Subtitle
- Definitive IMRT for Stage III Thymic Carcinoma: A Brief Report and Literature Review
- Creators
- Sarah A. Dooley - Roy J. and Lucille A. Carver College of MedicineCarryn M. Anderson - University of Iowa
- Resource Type
- Journal article
- Publication Details
- Frontiers in oncology, Vol.6, p.219
- DOI
- 10.3389/fonc.2016.00219
- PMID
- 27822456
- PMCID
- PMC5075761
- NLM abbreviation
- Front Oncol
- ISSN
- 2234-943X
- eISSN
- 2234-943X
- Publisher
- Frontiers Media Sa
- Number of pages
- 4
- Grant note
- P30 CA086862 / NCI NIH HHS; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI) P30CA030199 / NATIONAL CANCER INSTITUTE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Cancer Institute (NCI)
- Language
- English
- Date published
- 10/24/2016
- Academic Unit
- Radiation Oncology
- Record Identifier
- 9984312979402771
Metrics
3 Record Views